1.头标区<--> 20110002 20110712090302656 wanfangdata wanfang@wanfangdata.com wanfangdata 2.主体<--> 胸部疾病杂志<--> 2.1 刊元数据<--> JTD 胸部疾病杂志 Journal of Thoracic Disease 2072-1439 11-5323/C 2.2 期元数据<--> 2011 3 2 2.3 文章元数据<--> 一个titles里面只能有一个title<--> immunogenic after all? Karl-Josef Kallen Ulrike Gnad-Vogt CureVac GmbH, Paul-Ehrlich-Stra遝 15, 72076 T黚ingen, Germany 2011 JTD201102001 Hauke Winter and colleagues (1) review the active immunotherapies in non-small cell lung cancer (NSCLC) which they rightly call the deadliest cancer in the world. Defying the efforts of researchers in the field, not a single pivotal trial has achieved a median overall survival (OS) of only one year in advanced NSCLC. Theoretically, cancer immunotherapies could result in long-term survival and hopefully, even cure of cancer patients. Yet, despite the desperate need for life-prolonging therapies in NSCLC, Winter and colleagues count only four randomized phase III trials with active immunotherapies in NSCLC, to which two randomized trials (2,3) with oral talactoferrin (TLF), an activator of dendritic cells leading to antigen-specific T-cell immunity (4,5) in advanced NSCLC could be added. So where does the disparity between therapeutic need and pivotal trials to address this need stem from? 10.3978/j.issn.2072-1439.2011.02.01 79 81 2.3 文章元数据<--> Kurt Ulm Department of Medical Statistics and Epidemiology, Technische Universitaet Munich, Munich, Germany 2011 JTD201102002 There is an ongoing discussion about the selection of the most appropriate primary endpoint in cancer trials. Most papers are comparing progression-free survival (PFS) with overall survival (OS). Alternatives could be disease-free survival (DFS) or time to treatment failure (TTF). Another option could be the quality of life. 10.3978/j.issn.2072-1439.2011.02.02 82 83 2.3 文章元数据<--> Prognostic factors and long-term survival Francesco Ardissone Thoracic Surgery Unit, Department of Clinical & Biological Sciences, University of Turin, San Luigi Hospital, Orbassano (Torino), Italy 2011 JTD201102003 Thoracic solitary fibrous tumors (TSFTs) are uncommon neoplasms, with an estimated age-standardized incidence rate of 1.4 per million population (95% CI, 0.54-2.2) (1). 10.3978/j.issn.2072-1439.2011.03.05 84 85 2.2 期元数据<--> 2011 3 3 2.3 文章元数据<--> Successes and existing challenges Joe Y Chang Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2011 JTD201103001 non-small cell lung cancer; stage I; stereotactic radiotherapy Stereotactic ablative radiotherapy (SABR) has emerged as a standard treatment of peripherally located medically inoperable stage I non-small cell lung cancer (NSCLC) (1-5). With SABR, local control of primary tumors is greater than 90% in tumors up to 5 cm, and regional lymph node recurrence within the chest is low (5% to 10%). Distant metastasis remains a dominant pattern of failure (10% to 20%). SABR has been accepted by the National Comprehensive Cancer Network (NCCN) and is included in the NCCN treatment guidelines, and SABR is widely used (>75%) by radiation oncology centers, including community hospitals, according to a recent survey by the American Society for Radiation Oncology (ASTRO). 10.3978/j.issn.2072-1439.2011.06.02 144 146 心血管病诊断与治疗<--> 2.1 刊元数据<--> CDT 心血管病诊断与治疗 Cardiovascular Diagnosis and Therapy 2223-3652 11-5842/P 2.2 期元数据<--> 2011 1 1 2.3 文章元数据<--> Paul Schoenhagen J鰎g Hausleiter Stephan Achenbach Milind Y. Desai E. Murat Tuzcu Cardiovascular Imaging, Cleveland Clinic, 9500 Euclid Ave, Desk J 1-4, Cleveland, OH 44195. 2011 CDT201108001 Aortic Stenosis; Transcatheter Aortic Valve Implantation; Imaging; Computed Tomography If left untreated, symptomatic, severe aortic stenosis (AS) is associated with a dismal prognosis. Open-heart surgical valve replacement is the treatment of choice and is associated with excellent short and long-term outcome. However, many older patients with multiple co-morbidities and anticipated increased surgical risk are excluded from surgical intervention. For these patients, transcatheter aortic valve implantation (TAVI) is emerging as a viable treatment alternative. Transcatheter valvular heart procedures are characterized by lack of exposure and visualization of the operative field, therefore relying on image guidance, both for patient selection and preparation and the implantation procedure itself. This article describes the role of multi-detector row computed tomography (MDCT) for detailed assessment of the aortic valve, aortic root, and iliac arteries in the context of TAVI. 10.3978/j.issn.2223-3652.2011.08.01 1 12 胃肠肿瘤杂志<--> 2.1 刊元数据<--> JGO 胃肠肿瘤杂志 Journal of Gastrointestinal Oncology 2078-6891 61-1154/TG 2.2 期元数据<--> 2011 2 3 2.3 文章元数据<--> 一个titles里面只能有一个title<--> Current standards, research updates and future directions Chung-Tsen Hsueh Division of Medical Oncology and Hematology, Loma Linda University Medical Center, Loma Linda, California, USA 2011 JGO201103005 Pancreatic cancer; Ultrasound; Computed tomography; Magnetic resonance imaging; Endoscopic ultrasound guided fine needle aspiration Adenocarcinoma of pancreas is the fourth most common cause of cancer-related death among U.S. men and women. Due to lack of specific symptoms and effective screening modality, about 80% of pancreatic cancer cases are diagnosed at advanced stage with locally advanced or metastatic disease. Surgical resection remains the only curative therapy for pancreatic cancer patients, and 5-year survival for surgically resected patients is only 30%. Therefore, more research and novel strategies are urgently needed to understand biology better, detect the disease sooner, and develop better treatment to improve survival and quality of life. In this focused issue, we have covered important topics related to biology, detection and treatment of pancreatic cancer. 10.3978/j.issn.2078-6891.2011.037 123 125